research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
Search
for
Sort by
Research
870-900 / 1000+ results 
research A Study on the Role of Tofacitinib Among Patients Treated with Alopecia Areata
Tofacitinib effectively treats Alopecia Areata.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research Infundibular protein and RNA microarray analyses from affected and clinically non-affected scalp in male androgenetic alopecia patients
Finasteride helps female-pattern hair loss.
research Effects of oleanolic acid on hair growth in mouse dorsal skin mediated via regulation of inflammatory cytokines
Oleanolic acid improved hair growth in mice by affecting hair growth pathways and reducing inflammation.
research Minoxidil Sulfate Regulates JAK / STAT Signalling and Mitochondrial Function in Alopecia Areata
This study explores the effects of minoxidil sulfate (MXS) on alopecia areata (AA), an autoimmune hair disorder. MXS was found to enhance the anti-inflammatory effects of the JAK inhibitor baricitinib, leading to accelerated hair regrowth in patients. In human outer root sheath cells, MXS improved baricitinib's suppression of STAT1 phosphorylation and IFN-γ-inducible chemokines, while also independently inhibiting STAT1 and STAT3 activation. Additionally, MXS reduced mitochondrial stress and preserved immune privilege-associated features, suggesting its potential as an adjunctive treatment with JAK inhibitors without causing additional systemic immunosuppression.
research Finasteride nano-transferosomal gel formula for management of androgenetic alopecia: ex vivo investigational approach
NTF gel improves finasteride delivery for hair loss treatment, reducing side effects.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Investigation of intermolecular interactions in finasteride drug crystals in view of X-ray and Hirshfeld surface analysis
Finasteride crystals are held together by hydrogen bonds and weak interactions, forming synthon pseudopolymorphs.
research The usefulness of trichoscopy in the diagnosing of fibrosing alopecia in pattern distribution
Trichoscopy is crucial for accurately diagnosing fibrosing alopecia in pattern distribution.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research rPanglaoDB: an R package to download and merge labeled single-cell RNA-seq data from the PanglaoDB database
rPanglaoDB helps study rare cell types by merging RNA data, confirming fibrocytes' role in healing.
research Drug Discovery Insights from a Computational QSAR Study on Alpha-Reductase Inhibitors and Layered Double Hydroxides Electrocatalysts
Computational techniques can improve drug development for treating certain conditions.
research AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells
AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
research 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
research ROLE OF PLATELET-RICH PLASMA IN ANDROGENETIC ALOPECIA: A PROSPECTIVE STUDY
research Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata
Topical latanoprost doesn't effectively regrow hair in severe eyebrow alopecia areata cases.
research Skin iconography analysis of traumatic anserine folliculosis: Skin image feature of TAF
TAF can be identified by excessive skin thickening and clogged hair follicles, helping distinguish it from similar skin conditions.
research TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
research MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
research Use of Topical Minoxidil, 17α-Estradiol and Hydrocortisone Butyrate in Frontal Fibrosing Alopecia
A lotion with minoxidil, hydrocortisone butyrate, and 17a-estradiol can improve or stabilize Frontal Fibrosing Alopecia in some cases, but there's no universally-accepted treatment yet.
research Effects of In Utero Exposure to D-004, a Lipid Extract from Roystonea regia Fruits, in the Male Rat: A Comparison with Finasteride
D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study
A retrospective study involving 30 patients assessed the long-term efficacy and safety of upadacitinib for alopecia areata over at least 12 months. The study found high response rates of 90.0%, 80.0%, and 56.67% at month 12, with an upward trend over time. Patients with an atopic background showed better early-stage improvement in SALT scores compared to those without. No serious adverse events were reported, indicating favorable safety. Despite being a single-center study with a small sample size, the findings suggest that upadacitinib is effective and safe for long-term treatment of alopecia areata, particularly benefiting those with an atopic background.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Desenvolvimento de formulação lipídica nanoestruturada utilizando miristato de miristila no carreamento de estradiol
A new lipid-based formula using myristyl myristate can improve estradiol treatment for hair loss.
research The Frontal Fibrosing Alopecia Treatment Dilemma
Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
research C19and C215β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*
Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
The updated integrated safety analysis of the ALLEGRO clinical trials evaluated the long-term safety of ritlecitinib in patients aged 12 years and older with alopecia areata over approximately 5 years. The study included 1,294 patients in the any-ritlecitinib group and 1,228 in the ritlecitinib 50 mg ± 200 mg group. Adverse events (AEs) were common, occurring in 87.1% of the 50 mg ± 200 mg group and 89.5% of the any-ritlecitinib group, with headache, positive SARS-CoV-2 test, and nasopharyngitis being the most frequent. Serious AEs were reported in 6.8% of patients in both groups. The incidence rates for opportunistic infections, herpes zoster, malignancies, and major adverse cardiovascular events were low. Overall, the safety profile of ritlecitinib was consistent with previous data, indicating it was generally well tolerated for long-term use in this patient population.